S240
Clinical - Breast
ESTRO 2026
less toxic and more effective interventions, a clear consensus for routine brain imaging screening in asymptomatic BC survivors remains unestablished. This study aimed to assess how the method of BM detection (symptomatic vs. incidental on follow-up imaging) influences the choice of radiotherapy modality and subsequent patient outcomes. Material/Methods: We conducted a retrospective cohort study involving all BC patients treated for BM at a single public radiotherapy center in Brazil between 2010 and 2022. Clinical data, including how brain metastases were diagnosed, were meticulously reviewed. Statistical analyses were performed using R. Results:
higher conformity indices. Overall, all techniques achieved clinically acceptable plans with consistent dosimetric quality across patients.
Conclusion: This feasibility study demonstrates that modern VMAT can replicate the dosimetric advantages of DIBH while minimizing patient discomfort and streamlining treatment delivery. The findings indicate that DIBH may not be necessary for every patient, especially when advanced planning and delivery techniques are implemented. Further investigation of SIB and SIB-BH in a larger, more heterogeneous cohort is warranted to validate these preliminary observations and better define patient selection criteria for DIBH use. References: Darby SC et al. N Engl J Med. 2013;368:987– 998.Offersen BV et al. Radiother Oncol. 2022;167:44– 66. Keywords: DIBH, breast, radiotherapy Digital Poster 1408 The impact of brain metastases screening in breast cancer patients on radiotherapy modality Arthur Bom Queiroz 1,2 , Lucas Uglione Da Ros 1,3 , Ana Elisabeth Leal Varjão 2 , Valentina de Souza Stanham 1 , Laura Lessa Gaudie-Ley 1 , Marta Nassif Pereira Lima 1,4 , Daniela Dornelles Rosa 5,2 1 Radiotherapy, HCPA, Porto Alegre, Brazil. 2 PPGCM, UFRGS, Porto Alegre, Brazil. 3 PPGFT, UFRGS, Porto Alegre, Brazil. 4 Radiotherapy, Hospital Moinhos de Vento, Porto Alegre, Brazil. 5 Oncology, HCPA, Porto Alegre, Brazil Purpose/Objective: Breast cancer (BC) is the most common cancer among women, representing up to 29% of the new cancer cases in Brazil. Brain metastases (BM) are a significant source of morbidity and mortality in BC patients, despite implementation of screening programs for early detection and advancements in systemic treatment. While earlier diagnosis of BM can enable
In total, 122 patients were included, with a median age at diagnosis of 48.7 years. 50,8 % were Luminal B, 17 % were Luminal A, 14 % were HER2 positive and 14 % were triple negative. The median follow-up time to develop brain metastasis was 28.3 months. 108 patients received WBRT (88,5%) and 14 received SRS (11,5%). A significant association was observed between SRS utilization and lesions identified
Made with FlippingBook - Share PDF online